Macfarlanes advises Perrigo on £156m sale of its Rosemont Pharmaceuticals business

19 June 2020

Macfarlanes has advised Perrigo Company plc, an NYSE-listed leading global self-care company, on the sale of its Rosemont Pharmaceuticals business to a UK-headquartered private equity firm for £156m.

The sale of Rosemont Pharmaceuticals, which specialises in manufacturing generic liquid prescription medicines, is in line with Perrigo’s strategy to become a more consumer-focused self-care company.  

The transaction was signed and closed on the same day.

The Macfarlanes team for this matter was led by corporate and M&A partner Harry Coghill with assistance from senior solicitor Nicholas Page and solicitor Jonathan Webb. Commercial advice came from partner Malcolm Walton and solicitor Robert Grant, with real estate expertise provided by partner Tom Pedder. Input on the tax considerations came from senior solicitor Laura Foley, with employment advice provided by senior solicitor Chris Boyle.

Harry Coghill comments: “We were thrilled to assist Perrigo on this strategic transaction which completed successfully despite the unusual operating environment due to the coronavirus lockdown.”